TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3577278
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g Mezlocillin (Baypen) i.v.
Study: 23873670
Drug: ONO‐5334 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO‐5334 50 mg twice daily
Study: 23873670
Drug: ONO‐5334 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO‐5334 100 mg once daily
Study: 23873670
Drug: ONO‐5334 300 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO‐5334 300 mg once daily
Study: 23873670
Drug: Alendronate 70 mg
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate 70 mg once weekly
Study: 15968885
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of S-3304 (10 - 800 mg)
Study: 15968885
Drug: Multiple dose
Normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose of S-3304 (200 mg, 400 mg, 800 mg b.i.d.)
Study: 15968885
Drug: Multiple dose
Normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose of S-3304 (800 mg b.i.d.)
Study: 15968885
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of S-3304 (800 mg)
Study: 15968885
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of S-3304 (high-fat diet effect)
Study: 15968885
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of S-3304
Study: 15968885
Drug: S-3304 (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-3304 (800 mg b.i.d.)
Study: 14629247
Drug: Ergotamine tartrate
Normalized name: Ergotamine Tartrate
DrugBank: Ergotamine (DB00696)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ergotamine tartrate 2 mg
Study: 11307227
Drug: Oral Health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Health Status Questionnaire (OHSQ)
Study: 8885732
Drug: Terbutaline 5
Normalized name: terbutaline 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline 5 mg orally every 4 hours
Study: 8885732
Drug: Magnesium chloride
Normalized name: Magnesium Chloride
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium chloride 128 mg orally every 4 hours
Study: 8402734
Drug: 0.18 MIU/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.18 MIU/m2 IL-2 s.c. once weekly
Study: 8402734
Drug: 0.9 MIU/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 MIU/m2 IL-2 s.c. thrice weekly every other day
Study: 8402734
Drug: 4.5 MIU/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 MIU/m2 IL-2 s.c. five times weekly every other week
Study: 3710959
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g aztreonam iv twice daily for 4 to 15 days
Study: 3710959
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g cefotaxime iv twice daily for 4 to 15 days
Study: 29413437
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for NAS
Study: 18767580
Drug: Scalp acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scalp acupuncture combined with rehabilitation therapy (group C)
Study: 18767580
Drug: Rehabilitation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation therapy (group B)
Study: 16507374
Drug: Calcium +
Normalized name: Calcium + D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium + Vitamin D (calcium carbonate 500 mg and vitamin D3 400 IU taken twice daily)
Study: 12358234
Drug: Lansoprazole (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (15 mg or 30 mg once daily)
Study: 3915459
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg b.i.d.)
Study: 1860433
Drug: Endotracheal suction
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endotracheal suction 6-hourly
Study: 1860433
Drug: Endotracheal suction
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endotracheal suction 12-hourly
Study: 6434794
Drug: Glibenclamide 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide 10 mg/d for 6 weeks
Study: 29907752
Drug: microcrystalline cellulose
Normalized name: Microcrystalline Cellulose
DrugBank: Microcrystalline cellulose (DB14158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: microcrystalline cellulose pellets (500 mg samples)
Study: 20093909
Drug: Daily gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily gentamicin (5 mg/kg IV, then 2 placebo doses IV after 8 and 16 hours)
Study: 20093909
Drug: 8-hour gentamicin
Normalized name: gentamicin 0.8 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-hour gentamicin (2 mg/kg IV, then 1.5 mg/kg IV after 8 and 16 hours)
Study: 20093909
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received ampicillin (2 grams IV every 6 hours for a total of four doses) and patients who underwent cesarean delivery also received clindamycin (900 mg IV every 8 hours, for a total of three doses).
Study: 10207779
Drug: OAC 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC 20 regimen (Omeprazole 20 mg daily, Amoxycillin 500 mg t.d.s., Clarithromycin 200 mg b.d.)
Study: 10207779
Drug: LAC 30
Normalized name: etodolac 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAC 30 regimen (Lansoprazole 30 mg daily, Amoxycillin 500 mg t.d.s., Clarithromycin 200 mg b.d.)
Study: 10207779
Drug: OAC 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC 40 regimen (Omeprazole 20 b.d., Amoxycillin 500 mg t.d.s., Clarithromycin 200 mg b.d.)
Study: 334315
Drug: High dosage
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dosage haloperidol (100 mg daily) for three months
Study: 334315
Drug: High dosage
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dosage haloperidol (100 mg daily)
Study: 31385001
Drug: Quizartinib 30
Normalized name: quizartinib
DrugBank: Quizartinib (DB12874)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Quizartinib 30 mg alone (reference)
Study: 31385001
Drug: Lansoprazole 60
Normalized name: dexlansoprazole 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 60 mg once daily (days 1-5) + single-dose quizartinib 30 mg (day 5) (test)
Study: 26337978
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate 100 μg/vilanterol 25 μg once-daily
Study: 26337978
Drug: Existing therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Existing therapy (control group)
Study: 23578227
Drug: N7‐GP 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: N7‐GP 25 μg kg(‐1)
Study: 23578227
Drug: N7‐GP 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: N7‐GP 100 μg kg(‐1)
Study: 23578227
Drug: N7‐GP 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: N7‐GP 200 μg kg(‐1)
Study: 23578227
Drug: N7‐GP (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: N7‐GP (all doses)
Study: 23578227
Drug: Observation period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation period with on-demand treatment of rFVIIa
Study: 19188550
Drug: Bosentan (62.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan (62.5 mg on day 1, 125 mg on days 2 and 3)
Study: 17307892
Drug: Extracorporeal shockwave
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shockwave therapy (1500 impulses at 14 KV)
Study: 17307892
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (nonsteroidal anti-inflammatory drugs, physiotherapy, exercise program, knee strap)
Study: 14996107
Drug: 0.1% melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% melatonin applied once daily for 6 months
Study: 14996107
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution applied once daily for 6 months
Study: 11697758
Drug: Dofetilide (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dofetilide (0.5 mg bid)
Study: 11697758
Drug: Dofetilide (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dofetilide (0.5 mg bid) + Verapamil (80 mg tid)
Study: 10365287
Drug: Inogatran (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inogatran (low dose)
Study: 10365287
Drug: Inogatran (medium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inogatran (medium dose)
Study: 10365287
Drug: Inogatran (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inogatran (high dose)
Study: 3370405
Drug: Salad with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salad with toppings (600 g) with small beverage
Study: 3370405
Drug: Carbonated beverage
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbonated beverage (800 ml)
Study: 3370405
Drug: Bean burritos
Normalized name: Bean
DrugBank: Bean (DB14709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bean burritos and one bean tostada (900 g) with small beverage
Study: 29666118
Drug: Initial R-chemotherapy
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial R-chemotherapy ± R maintenance
Study: 26254752
Drug: Landiolol hydrochloride
Normalized name: Landiolol Hydrochloride
DrugBank: Landiolol (DB12212)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Landiolol hydrochloride (ultrashort‐acting β‐blocker)
Study: 23823157
Drug: Paclitaxel plus
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel plus cisplatin with twice-daily radiation
Study: 23823157
Drug: Fluorouracil plus
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil plus cisplatin with twice-daily radiation
Study: 18552270
Drug: Erythropoietin stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin stimulating agents (ESAs)
Study: 16616165
Drug: 21 mg
Normalized name: aspirin 421 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 mg nicotine patch (NP)
Study: 16616165
Drug: 42 mg
Normalized name: lithium 42 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 42 mg nicotine patch (NP)
Study: 15030300
Drug: Therapies targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapies targeted against reactive oxygen intermediates (not specified dosage or duration)
Study: 15030300
Drug: Antioxidants (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidants (not specified dosage or duration)
Study: 8618139
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (2000 or 3000 mg for 16 weeks)
Study: 6741150
Drug: 2 times
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 times 250 ml protein‐free dialysate of calf blood (Solcoseryl) in saline solution over 9 days
Study: 31619359
Drug: Topical natamycin
Normalized name: Natamycin
DrugBank: Natamycin (DB00826)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical natamycin 5% plus CXL
Study: 31619359
Drug: Topical natamycin
Normalized name: Natamycin
DrugBank: Natamycin (DB00826)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical natamycin 5% alone
Study: 31619359
Drug: Topical amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical amphotericin B 0.15% alone
Study: 24120672
Drug: Intradermal vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal vaccine (15μg HA/strain)
Study: 24120672
Drug: Intradermal vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal vaccine (21μg HA/strain)
Study: 24120672
Drug: High-dose intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intramuscular vaccine (60μg HA/strain)
Study: 24120672
Drug: Standard-dose intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose intramuscular vaccine (15μg HA/strain)
Study: 22674470
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution of 10 μg deuterated Phenanthrene ([D₁₀]Phe)
Study: 22674470
Drug: Smoking cigarettes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking cigarettes containing 10 μg deuterated Phenanthrene ([D₁₀]Phe)
Study: 12232564
Drug: Verapamil (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (0.15 mg/kg at a rate of 2 mg/min)
Study: 12232564
Drug: Ibutilide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibutilide (1 mg over 10 minutes)
Study: 10086657
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate (400 mg twice daily) plus metronidazole (400 mg) and tetracycline (500 mg) four times daily for 1 week (RMT)
Study: 10086657
Drug: Colloidal bismuth
Normalized name: Colloidal bismuth subcitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal bismuth subcitrate (120 mg), metronidazole (400 mg), and tetracycline (500 mg) four times daily for 1 week (BMT)
Study: 7394499
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg oxitropium bromide
Study: 7394499
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg oxitropium bromide at 7.30 a.m. after placebo
Study: 19438539
Drug: M. vaccae
Approvals — FDA: no, EMA: no, PMDA: no
Description: M. vaccae (intradermal injection, three times at 2-week intervals)
Study: 19438539
Drug: Placebo (intradermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intradermal injection, three times at 2-week intervals)
Study: 15145972
Drug: Omeprazole (OM)
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole (OM) 20 mg bid with bismuth biskalcitrate, metronidazole, and tetracycline
Study: 8076440
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 1 alpha‐OHD3 (80 ng/kg BW)
Study: 8076440
Drug: Intraperitoneal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal administration of 1 alpha‐OHD3 (80 ng/kg BW)
Study: 8076440
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 1 alpha‐OHD3 (80 ng/kg BW)
Study: 2760214
Drug: Estrogen therapy
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen therapy for 3 months
Study: 2760214
Drug: Chronic estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic estrogen therapy
Study: 30566177
Drug: Extended-release naltrexone
Normalized name: bupropion / naltrexone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release naltrexone (XR-NTX) 380 mg every 4 weeks
Study: 30566177
Drug: Buprenorphine-naloxone (BP-NLX)
Normalized name: buprenorphine / naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine-naloxone (BP-NLX) flexible doses (4-24 mg; target dosage 16 mg/d)
Study: 23625291
Drug: Plecanatide (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plecanatide (0.1 to 48.6 mg)
Study: 20971975
Drug: Rosiglitazone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (8 mg once daily for 8 weeks)
Study: 16769932
Drug: Active rTMS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active rTMS and placebo medication
Study: 12776447
Drug: Budesonide Turbuhaler
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide Turbuhaler (400 micrograms) once daily
Study: 10669275
Drug: Propacetamol 60
Normalized name: Propanetriol
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propacetamol 60 mg kg(‐1) i.v.
Study: 10669275
Drug: Ketorolac 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 0.4 mg kg(‐1) i.v.
Study: 9062568
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy combined with incentive spirometry (IS)
Study: 9062568
Drug: Postoperative pulmonary
Normalized name: Lobaria pulmonaria extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative pulmonary physical therapy (breathing exercises, secretion removal, mobility)
Study: 8406337
Drug: Human growth
Normalized name: Human growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human growth hormone (HGH) 4 IU/m2/day for 2 years
Study: 8406337
Drug: Human growth
Normalized name: Human growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human growth hormone (HGH) 3 IU/m2/day for 2 years
Study: 8406337
Drug: Human growth
Normalized name: Human growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human growth hormone (HGH) 2 IU/m2/day for 2 years
Study: 29579957
Drug: Treatment 1
Normalized name: CVS Acne Treatment 10% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment 1 - received general information and information about the benefits (positive attributes)
Study: 29579957
Drug: Treatment 2
Normalized name: epoch Blemish Treatment 2 % Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment 2 - received general information and information about the potential drawbacks (negative attributes)
Study: 12065968
Drug: Aqueous solution
Normalized name: Zephiran Chloride 1:750 Antiseptic Aqueous Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous solution of powdered sweetener (Zero Cal)
Study: 12065968
Drug: 1.5% lactose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% lactose solution
Study: 12065968
Drug: 1.5% sucrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% sucrose solution
Study: 9726444
Drug: rG‐CSF 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: rG‐CSF 5 microg/kg for 5 consecutive days starting 7 days before chemotherapy with etoposide and cisplatin.
Study: 9726444
Drug: Course 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Course 2 results after chemotherapy.
Study: 30689759
Drug: Azithromycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (1 g single dose)
Study: 7974076
Drug: Erythromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (500 mg 4 times daily for 7 days)
Study: 2566827
Drug: haem arginate
Normalized name: Haem arginate
DrugBank: Heme arginate (DB17310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: haem arginate 3 mg/kg per 24 h for 4 days
Study: 31948466
Drug: EPA +
Normalized name: Eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EPA + DHA (1.87 g/day of EPA + 1.0 g/day of DHA)
Study: 8099789
Drug: Cognitive Treatment
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Treatment (CT)
Study: 31127076
Drug: Physical Treatment
Normalized name: SUNSCREEN 30-50/PHYSICAL BLOCK/PABA-FREE, COMBO LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical Treatment (PT)
Study: 26323938
Drug: Control (guideline-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (guideline-based medical treatment alone)
Study: 9438480
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray (FPANS) 200 microg BD for 8 weeks
Study: 9438480
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray (FPANS) 200 microg OD for 8 weeks
Study: 9438480
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray (FPANS) 200 microg OD for 4 weeks followed by FPANS 200 microg BD for 4 weeks
Study: 9438480
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered twice daily for 8 weeks
Study: 8497284
Drug: Aerosolized tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Aerosolized tobramycin (600 mg for 28 days)
Study: 30891999
Drug: Bi-level positive
Normalized name: bis-ethoxydiglycol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bi-level positive airway pressure ventilation in addition to conventional treatment
Study: 30891999
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment including continuous oxygen inhalation, anti-infection, bronchodilation, phlegm resolving, nutrition support, analgesia, cardiac function maintenance, coronary dilatation, anticoagulation
Study: 21224868
Drug: Daily dose
Normalized name: LENVIMA 8mg Daily Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of 7.5 μg of vitamin D₃ for 12 months, increasing to 22.5 μg for the remaining 18 months through fortified dairy products and nutrition and lifestyle counselling sessions
Study: 19042080
Drug: ZD4054 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZD4054 10 mg
Study: 19042080
Drug: ZD4054 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZD4054 15 mg
Study: 16453185
Drug: Nipradilol 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nipradilol 0.25% twice daily for 3 months
Study: 16453185
Drug: Carteolol 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carteolol 2% twice daily for 3 months
Study: 15246467
Drug: Atypical antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotics (APDs) + Antidepressants
Study: 15246467
Drug: Atypical antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotics (APDs)
Study: 11726261
Drug: L-carnitine L-tartrate
Normalized name: L-carnitine (free form) (as L-carnitine L-tartrate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine L-tartrate (LCLT) 3 g/day for 3 weeks
Study: 9230328
Drug: Acetaminophen with
Normalized name: acetaminophen with codeine ORAL ELIXIR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen with codeine (group 1)
Study: 9230328
Drug: Ibuprofen (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (group 2)
Study: 8390548
Drug: Trivalent vaccine
Normalized name: Fluzone 2024-2025 trivalent vaccine Injectable Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent vaccine containing 10(4) TCID50 of B